Transport of selected PET radiotracers by human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2): An in vitro screening

Journal of Nuclear Medicine

Volumn 52, Issue 3, 2011, Pages 415-423

  Tournier, Nicolas ^a,b   Valette, Héric ^a   Peyronneau, Marie Anne ^a   Saba, Wadad ^a   Goutal, Sébastien ^a   Kuhnast, Bertrand ^a   Dollé, Frédéric ^a   Scherrmann, Jean Michel ^b,c   Cisternino, Salvatore ^b,c   Bottlaender, Michel ^a  

^a SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c INSERM   (France)

Author keywords

ABC proteins; Blood brain barrier; Breast cancer resistance protein; P glycoprotein; Positron emission tomography; Radiotracers

Indexed keywords

2 FLUORO 3 (2 AZETIDINYLMETHOXY)PYRIDINE; 4 (2' METHOXYPHENYL) 1 [2' [N (2'' PYRIDINYL) 4 FLOUROBENZAMIDO]ETHYL]PIPERAZINE; 4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; 8 (4 FLUORO BUT 2 ENYL) 3BETA 4 TOLYL 8 AZA BICYCLO[3.2.1]OCTANE 2BETA CARBOXYLIC ACID METHYL ESTER; BEFLOXATONE; BREAST CANCER RESISTANCE PROTEIN; CLORGYLINE; DIPRENORPHINE; DPA 714; FLUMAZENIL; LBT 999; LOPERAMIDE; MULTIDRUG RESISTANCE PROTEIN 1; N (3 IODOPROP 2 ENYL) 2BETA CARBOMETHOXY 3BETA (4' METHYLPHENYL)NORTROPANE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; N,N DIETHYL 2 [2 [4 (2 FLUOROETHOXY)PHENYL] 5,7 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDIN 3 YL]ACETAMIDE; PE 21; PITTSBURGH COMPOUND B; RACLOPRIDE; RADIOLIGAND; SELEGILINE; TRACER; UNCLASSIFIED DRUG; VALSPODAR; VERAPAMIL;

ANIMAL CELL; ARTICLE; BLOOD BRAIN BARRIER; IN VITRO STUDY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN FUNCTION; RADIOACTIVITY; TRANSPORT KINETICS;

ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT, ACTIVE; BLOOD-BRAIN BARRIER; CELL LINE; HUMANS; KIDNEY; NEOPLASM PROTEINS; P-GLYCOPROTEIN; RADIOPHARMACEUTICALS;

EID: 79952799894     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.079608     Document Type: Article

References (43)

1. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis. 2009;37:13-28.
2. Levran O, O'Hara K, Peles E, et al. ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum Mol Genet. 2008;17:2219-2227. (Pubitemid 351916578)
3. Park HJ, Shinn HK, Ryu SH, Lee HS, Park CS, Kang JH. Genetic polymorphisms in the ABCB1 gene and the effects of fentanyl in Koreans. Clin Pharmacol Ther. 2007;81:539-546. (Pubitemid 46452300)
4. Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther. 2006;112:457-473. (Pubitemid 44486412)
5. Kannan P, John C, Zoghbi SS, et al. Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin Pharmacol Ther. 2009;86:368-377.
6. Pike VW. PET radiotracers: crossing the blood-brain barrier and surviving metabolism. Trends Pharmacol Sci. 2009;30:431-440.
7. Giacomini KM, Huang S, Tweedie DJ, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9:215-236.
8. 99mtechnetium sestamibi more than inhibiting Abcb1, Abcc1, or Abcg2. J Neurochem. 2009;108:767-775.
9. Takeuchi T, Yoshitomi S, Higuchi T, et al. Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1. Pharm Res. 2006;23:1460-1472. (Pubitemid 43993809)
10. Syvänen S, Lindhe O, Palner M, et al. Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug Metab Dispos. 2009;37:635-643.
11. Sasongko L, Link JM, Muzi M, et al. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther. 2005;77:503-514. (Pubitemid 40824964)
12. 11C-N-desmethylloperamide. J Nucl Med. 2010;51:559-566.
13. Vlaming ML, Lagas JS, Schinkel AH. Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice. Adv Drug Deliv Rev. 2009;61:14-25.
14. 18F]DPA-714, a selective radioligand for imaging the translocator protein (18 kDa) with PET. J Labelled Comp Radiopharm. 2008;51:286-292.
15. Dollé F, Dolci L, Valette H, et al. Synthesis and nicotinic acetylcholine receptor in vivo binding properties of 2-fluoro-3-[2(S)-2- azetidinylmethoxy]pyridine: a new positron emission tomography ligand for nicotinic receptors. J Med Chem. 1999;42:2251-2259. (Pubitemid 29284245)
16. 18F]LBT-999, a selective radioligand for the visualisation of the dopamine transporter with PET. J Labelled Comp Radiopharm. 2007;50:716-723.
17. Emond P, Garreau L, Chalon S, et al. Synthesis and ligand binding of nortropane derivatives: N-substituted 2beta-carbomethoxy-3beta-(4′- iodophenyl)nortropane and N-(3-iodoprop-(2E)-enyl)-2beta-carbomethoxy-3beta- (3′,4′-disubstituted phenyl) nortropane - new high-affinity and selective compounds for the dopamine transporter. J Med Chem. 1997;40:1366-1372. (Pubitemid 27198083)
18. 18F] fallypride on a TRACERLab FX-FN synthesizer [abstract]. J Labelled Comp Radiopharm. 2009;52(suppl 1):S286.
19. Tournier N, Chevillard L, Megarbane B, Pirnay S, Scherrmann JM, Decleves X. Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int J Neuropsychopharmacol. 2010;13:905-915.
20. Mahar Doan KM, Humphreys JE, Webster LO, et al. Passive permeability and Pglycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002;303:1029-1037. (Pubitemid 35424386)
21. Luna-Tortos C, Fedrowitz M, Loscher W. Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology. 2008;55:1364-1375.
22. Goh LB, Spears KJ, Yao D, et al. Endogenous drug transporters in in vitro and in vivo models for the prediction of drug disposition in man. Biochem Pharmacol. 2002;64:1569.
23. Suzuyama N, Katoh M, Takeuchi T, et al. Species differences of inhibitory effects on P-glycoprotein-mediated drug transport. J Pharm Sci. 2007;96:1609-1618. (Pubitemid 46953775)
24. Dauchy S, Dutheil F, Weaver RJ, et al. ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood-brain barrier. J Neurochem. 2008;107:1518-1528.
25. Pavek P, Merino G, Wagenaar E, et al. Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1- methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine. J Pharmacol Exp Ther. 2005;312:144-152. (Pubitemid 40096463)
26. Robey RW, Steadman K, Polgar O, et al Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res. 2004;64:1242-1246. (Pubitemid 38235589)
27. 99mTc-tricarbonyl: synthesis and transport at the mouse blood-brain barrier. J Pharm Sci. 2009;98:4650-4660.
28. Kiyono Y, Yamashita T, Doi H, et al. Is MIBG a substrate of P-glycoprotein? Eur J Nucl Med Mol Imaging. 2007;34:448-452.
29. Ishiwata K, Kawamura K, Yanai K, Hendrikse NH. In vivo evaluation of Pglycoprotein modulation of 8 PET radioligands used clinically. J Nucl Med. 2007;48:81-87.
30. 11C](R)-(-)-RWAY. Synapse. 2007;61:96-105.
31. 18F]MPPF uptake in rat brain and peripheral tissues: microPET and ex vivo studies. Eur J Nucl Med Mol Imaging. 2008;35:2256-2266.
32. Elsinga PH, Hendrikse NH, Bart J, van Waarde A, Vaalburg W. Positron emission tomography studies on binding of central nervous system drugs and Pglycoprotein function in the rodent brain. Mol Imaging Biol. 2005;7:37-44. (Pubitemid 41348874)
33. 11C](R)-(2)-RWAY. Synapse. 2006;60:510-520.
34. 1 receptors in nonhuman primate brain. Neuropsychopharmacology. 2008;33:259-269.
35. Crowley E, Callaghan R. Multidrug efflux pumps: drug binding: gates or cavity? FEBS J. 2010;277:530-539.
36. Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, Callaghan R. Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol. 2000;58:624-632.
37. Hamill TG, Sato N, Jitsuoka M, et al. Inverse agonist histamine H3 receptor PET tracers labelled with carbon-11 or fluorine-18. Synapse. 2009;63:1122-1132.
38. Varma MV, Sateesh K, Panchagnula R. Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport. Mol Pharm. 2005;2:12-21. (Pubitemid 40314725)
39. 11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation. Nucl Med Biol. 2003;30:747-751.
40. Hassan HE, Myers AL, Coop A, Eddington ND. Differential involvement of Pglycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation. J Pharm Sci. 2009;98:4928-4940.
41. 11C]diprenorphine to agonist opiates. J Pharmacol Exp Ther. 2007;322:661-667.
42. Walter RB, Pirga JL, Cronk MR, Mayer S, Appelbaum FR, Banker DE. PK11195, a peripheral benzodiazepine receptor (PBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a PBR-independent, direct transporter-modulating mechanism. Blood. 2005;106:3584-3593. (Pubitemid 41609197)
43. 11C] befloxatone and the multiinjection approach. J Cereb Blood Flow Metab. 2010;30:792-800.